DIAGNOS Provides Update on its CARA AI Application Participating in US White House Call to Action Data Analysis Program
April 27 2020 - 9:04AM
DIAGNOS Inc. (“
DIAGNOS” or the
“
Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF),
a leader in early detection of critical health issues using
advanced Artificial Intelligence (AI) tools, provides an update on
its
CARA (Computer Assisted Retinal Analysis) AI
Application, following the Corporation’s participation in the US
White House call to action data analysis program
(“
Program”), as referred to in the Corporation’s
March 25, 2020 press release. Pursuant to the Corporation’s
analysis of the technical details sourced from the Program, it is
developing a new add-on test to CARA to provide an innovative
solution for COVID-19 patients by offering a means to monitor
health through retina analysis. DIAGNOS’ scientific team has been
able to link the Corporation’s core business application of its
CARA technology for early onset of blindness caused by Diabetes to
assess the effects of COVID-19 on patients.
In an effort to help patients exposed to the
COVID-19 virus, DIAGNOS is formulating a test by means of its CARA
application to monitor the short and long-term effects of the virus
through retina analysis and its proprietary advanced detection
algorithm. In the Open Research Dataset (CORD-19), DIAGNOS has
identified evidence of the impact of certain medication that
affects the retina of the eye, more specifically diabetic patients.
This dataset continues to provide valuable information that address
questions DIAGNOS is exploring in order to increase the
functionality of its CARA application, for instance analyzing the
tendency for asymptomatic patients to develop increased retinopathy
symptoms that DIAGNOS could subsequently identify.
Mr. André Larente, CEO of
DIAGNOS stated: “Through the use of the
information contained in the CORD-19 dataset we have gathered from
the US government Call-to-action”, DIAGNOS’ AI platform is
currently being modified in order to add innovative testing tools
to help identify the effects of the COVID-19 virus. The AAO
(American Academy of Ophthalmology) has already identified certain
medications that clearly demonstrate an impact on the retina.
Through the use of a fundus test, such as the one that we provide,
we could add a test for this specific pathology. We are testing our
technology to see if we can eventually provide the proper solution
to build on our existing tests tools.”
About DIAGNOS
DIAGNOS is a publicly traded Canadian
corporation with a mission of early detection of critical health
issues through the use of its Artificial Intelligence (“AI”)
platform FLAIRE. Using the FLAIRE platform, DIAGNOS is able to
build and further extend rapidly its applications such as CARA
(Computer Assisted Retina Analysis). CARA’s Artificial Intelligence
image enhancement algorithms make standard retinal images sharper,
clearer and easier to read. CARA is a cost-effective tool for
screening a large number of patients in real-time and has been
cleared for commercialization by several regulatory authorities
including Health Canada, the U.S. Food and Drug Administration,
European Union and other countries.
Additional information is available at
www.diagnos.com and www.sedar.com.
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. For further information,
please contact:
Mr. André Larente, PresidentDIAGNOS Inc. Tel:
450-678-8882 ext. 224alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024